| Total no. patients enrolled in MDS 98-21 | |
| On study | 51 |
| Off study | 32 |
| Median age of patients, y | 67 |
| Sex | |
| Male | 55 |
| Female | 28 |
| FAB | |
| RA | 36 |
| RAEB | 24 |
| RAEB-t | 6 |
| RARS | 13 |
| CMMoL | 4 |
| MDS duration, d | |
| Median | 426 |
| Range | 9-3351 |
| Transfusion history | |
| PRBC dependent | |
| Yes | 63 |
| No | 20 |
| Platelet dependent | |
| Yes | 21 |
| No | 62 |
| Primary/secondary MDS | |
| Primary | 77 |
| Secondary | 6 |
| IPSS | |
| Low | 21 |
| INT-1 | 37 |
| INT-2 | 12 |
| High | 13 |
| Biopsy cellularity | |
| Hyper | 54 |
| Normal | 14 |
| Hypo | 12 |
| Thalidomide dose by duration, wk | |
| 400 mg for at least 8 weeks | 8 |
| 400 mg for less than 8 weeks | 36 |
| 200 mg to 350 mg | 28 |
| Less than 200 mg | 10 |
| Total no. patients enrolled in MDS 98-21 | |
| On study | 51 |
| Off study | 32 |
| Median age of patients, y | 67 |
| Sex | |
| Male | 55 |
| Female | 28 |
| FAB | |
| RA | 36 |
| RAEB | 24 |
| RAEB-t | 6 |
| RARS | 13 |
| CMMoL | 4 |
| MDS duration, d | |
| Median | 426 |
| Range | 9-3351 |
| Transfusion history | |
| PRBC dependent | |
| Yes | 63 |
| No | 20 |
| Platelet dependent | |
| Yes | 21 |
| No | 62 |
| Primary/secondary MDS | |
| Primary | 77 |
| Secondary | 6 |
| IPSS | |
| Low | 21 |
| INT-1 | 37 |
| INT-2 | 12 |
| High | 13 |
| Biopsy cellularity | |
| Hyper | 54 |
| Normal | 14 |
| Hypo | 12 |
| Thalidomide dose by duration, wk | |
| 400 mg for at least 8 weeks | 8 |
| 400 mg for less than 8 weeks | 36 |
| 200 mg to 350 mg | 28 |
| Less than 200 mg | 10 |
MDS, myelodysplastic syndrome; FAB, French-American-British classification; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; RARS, RA with ringed sideroblasts; CMMoL, chronic myelomonocytic leukemia; PRBC, packed red blood cell transfusion; platelet, platelet transfusion; IPSS, International Prognostic Scoring System; low, low-risk group; INT-1, intermediate-I risk group; INT-2, intermediate-II risk group; high, high-risk group.